癫痫相关影响评估量表的验证:一种新型患者报告结局指标
本研究前瞻性纵向招募90例成人癫痫患者,验证癫痫相关影响评估量表(SERIAS)的信效度。SERIAS包含6个自评条目,总分0-150分,分数越高表示残疾越重。结果显示SERIAS与QOLIE-31、EQ-5D、NDDI-E、GAD-7、SSS-8、LAEP及WSAS等量表均显著相关,心理测量信度和重测信度可接受。
要点
- SERIAS是一种评估癫痫相关残疾的患者报告结局量表,总分0-150分。
- SERIAS与多个验证量表(QOLIE-31、EQ-5D、NDDI-E等)显著相关,信效度良好。
- SERIAS重测信度ICC=0.72(95%CI 0.51-0.85),心理测量信度系数均>0.70。
核心结论
- SERIAS显示出良好的心理测量信度和较强的重测稳定性,是测量癫痫相关残疾的有效量表。
研究设计与样本
- 前瞻性纵向研究,从澳大利亚综合癫痫中心招募成人癫痫患者,基线及3、6个月后完成SERIAS。
- 共90例患者完成基线SERIAS(64.4%女性,平均年龄43.1岁)。
主要发现
- 62%患者报告至少1天残疾,SERIAS中位评分3分(四分位距18.3)。
- SERIAS评分与QOLIE-31总分负相关(β=-0.17,95%CI -0.27至-0.07)。
- SERIAS评分与5级EQ-5D(β=0.15,95%CI 0.04-0.25)、NDDI-E(β=0.22,95%CI 0.13-0.31)、GAD-7(β=0.21,95%CI 0.09-0.32)、SSS8(β=0.29,95%CI 0.17-0.41)、LAEP(β=0.29,95%CI 0.20-0.39)正相关。
- SERIAS评分与WSAS癫痫相关不良事件(β=0.23,95%CI 0.14-0.33)及治疗相关不良事件(β=0.36,95%CI 0.26-0.46)正相关。
- 更高发作频率与更高SERIAS评分相关(β=0.07,95%CI 0.03-0.11)。
关键数值与推荐
- SERIAS包含6个自评条目:5项记录每月因发作或治疗相关不良事件部分或完全影响工作/家庭/学校及家庭/社交/非工作活动的天数,1项为癫痫残疾视觉模拟量表。
- SERIAS总分为每月残疾天数之和,范围0-150分,分数越高表示残疾越重。
- 心理测量信度所有系数>0.70,重测信度ICC=0.72(95%CI 0.51-0.85,n=35)。
临床怎么用
- SERIAS可作为癫痫临床试验和临床实践中评估发作与治疗相关不良事件权衡的可靠患者报告结局工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: There is a clear need in epilepsy clinical trials and practice for a measure that captures the trade-off between seizure and treatment-related adverse effects, which is reliable over time and across different treatment regimens. We aimed to create and validate the Seizure-Related Impact Assessment Scale (SERIAS) to fill this need. METHODS: This was a prospective longitudinal study of adults with epilepsy recruited from an Australian comprehensive epilepsy center. Participants completed SERIAS at baseline and 3 and 6 months later. SERIAS has 6 self-report items. Five items record the number of days per month that seizures or treatment-related adverse effects partially or fully affect work/home/school and family/social/nonwork activities. The final item is an epilepsy disability visual analog scale. SERIAS is scored by adding the days per month of disability, with scores ranging from 0 to 150 (higher scores indicate more disability). SERIAS was completed alongside 7 validated instruments measuring seizure-related and treatment-related adverse effects (Work and Social Adjustment Scale [WSAS], Liverpool Adverse Events Profile [LAEP]), mood disorders (Neurological Disorders Depression Inventory for Epilepsy [NDDI-E], Generalized Anxiety Disorder [GAD-7]), somatic symptoms (Somatic Symptom Scale [SSS-8]), and quality of life (Quality of Life in Epilepsy Inventory [QOLIE]-31, EuroQol 5 Dimensions [EQ-5D]). General linear mixed models were used to investigate the relationship between the SERIAS and other relevant clinical and psychometric data. Standardized model coefficients β are presented with 95% confidence intervals. RESULTS: A total of 90 patients (64.4% female, mean age 43.1 years) completed baseline SERIAS. Most patients reported at least 1 day of disability (62%, median SERIAS score = 3, interquartile range = 18.3). Greater disability was negatively correlated with QOLIE-31 total score (β = -0.17, 95% CI -0.27 to -0.07) and positively correlated with scores on 5-level EQ-5D (β = 0.15, 95% CI 0.04-0.25), NDDI-E (β = 0.22, 95% CI 0.13-0.31), GAD-7 (β = 0.21, 95% CI 0.09-0.32), SSS8 (β = 0.29, 95% CI 0.17-0.41), LAEP (β = 0.29, 95% CI 0.20-0.39), WSAS seizure-related adverse events (β = 0.23, 95% CI 0.14-0.33), and WSAS treatment-related adverse events (β = 0.36, 95% CI 0.26-0.46). Higher seizure frequency was associated with higher SERIAS score (β = 0.07, 95% CI 0.03-0.11). Psychometric reliability for the SERIAS was acceptable (all coefficients >0.70) as was test-retest reliability (n = 35 patients, intraclass correlation coefficient = 0.72, 95% CI 0.51-0.85). DISCUSSION: SERIAS shows good psychometric reliability and strong test-retest stability. These findings suggest that SERIAS is a valid scale to measure epilepsy-related disability.
引用
- Foster E, Conquest A, Ewart C, et al. Validation of the Seizure-Related Impact Assessment Scale: A Novel Patient-Reported Outcome Measure for Epilepsy. Neurology. 2025. PMID: 40669025. doi:10.1212/WNL.0000000000213900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。